Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 1,348 matching trials from the live ClinicalTrials.gov search.
Recruiting Not applicable Interventional

STIMIT Activator 1 IDE Study

NCT05883163
Conditions
Diaphragm Issues
Interventions
Stimit Activator 1
Device
Lead sponsor
Stimit AG
Industry
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
New Haven, Connecticut • Boston, Massachusetts • Charlottesville, Virginia
Completed Not applicable Interventional Results available

Heart Watch Study: a Pragmatic Randomized Controlled Trial

NCT04468321
Conditions
Cardioversion, Atrial Fibrillation
Interventions
Apple Watch, Withings Move
Device
Lead sponsor
Yale University
Other
Eligibility
22 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
New Haven, Connecticut • Rochester, Minnesota • Durham, North Carolina
Conditions
Atrial Fibrillation, Cerebrovascular Accident, Death, Sudden
Interventions
Amiodarone, Sotalol
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Enrollment
706 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
28
States / cities
Tucson, Arizona • No. Little Rock, Arkansas • Fresno, California + 25 more
Conditions
Bone Age
Interventions
BoneAgeModel
Device
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
1,903 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
6
States / cities
Stanford, California • New Haven, Connecticut • Boston, Massachusetts + 3 more
Conditions
Urinary Tract Infections, Sepsis
Interventions
Gentamicin, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Ischemic Stroke
Interventions
Endovascular thrombectomy with any FDA-approved category POL or NRY device, Medical Management
Device · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
41
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 34 more
Conditions
Urothelial Cancer
Interventions
Avelumab, Best Supportive Care, Following the planned interim analysis for this study: Avelumab
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
19
States / cities
Aurora, Colorado • New Haven, Connecticut • Boston, Massachusetts + 4 more
Conditions
Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, KRAS G12V
Interventions
AFNT-211
Drug
Lead sponsor
Affini-T Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
10
States / cities
Los Angeles, California • New Haven, Connecticut • New York, New York + 5 more
Conditions
Atherosclerosis
Interventions
Selnoflast, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
24
States / cities
Beverly Hills, California • Irvine, California • Los Angeles, California + 19 more
Conditions
Heart Failure, Acute Kidney Injury
Interventions
Dapagliflozin 10mg Tab, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 85 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
2
States / cities
New Haven, Connecticut
Conditions
Healthy
Interventions
PF-04965842, Probenecid
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction
Interventions
Omecamtiv Mecarbil (OM), Placebo
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
88
States / cities
Alexander City, Alabama • Birmingham, Alabama • Tucson, Arizona + 77 more
Conditions
Chronic Kidney Diseases, Hypertension
Interventions
Re-timing of anti-hypertensive drug, Current regimen
Other
Lead sponsor
Yale University
Other
Eligibility
6 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Diabetes Mellitus, Type 2
Interventions
Gan & Lee Insulin Glargine Injection, Lantus®
Biological
Lead sponsor
Gan and Lee Pharmaceuticals, USA
Industry
Eligibility
18 Years to 75 Years
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
57
States / cities
Birmingham, Alabama • Tuscumbia, Alabama • Phoenix, Arizona + 45 more
Conditions
Low-grade Serous Ovarian Cancer, Low-grade Serous Fallopian Tube Cancer, Low-grade Serous Peritoneal Cancer
Interventions
MEK162, MEK inhibitor; oral, Physician's choice chemotherapy
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
77
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 37 more
Conditions
Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
Interventions
Insulin Efsitora Alfa, Insulin Lispro (U100), Insulin Glargine (U100)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
24
States / cities
Hamden, Connecticut • Clearwater, Florida • Miami Lakes, Florida + 19 more
Conditions
Healthy Participants
Interventions
PF-06842874, Placebo, Relative Bioavailability
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
New Haven, Connecticut
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Study of PF-05230907 in Healthy Japanese Subjects

NCT02537002
Conditions
Healthy
Interventions
PF-05230907, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 45 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Bioavailability
Interventions
PF-07321332/ritonavir, PF-07321332
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Stage III Colon Cancer
Interventions
Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
Device · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
1,912 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1037
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 723 more
Active, not recruiting Not applicable Interventional

SELUTION 4 De Novo Small Vessel IDE Trial

NCT05946629
Conditions
Coronary Artery Disease
Interventions
PCI with SELUTION SLR DCB, PCI with FDA approved "-limus" DES
Device
Lead sponsor
M.A. Med Alliance S.A.
Industry
Eligibility
18 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
65
States / cities
Jonesboro, Arkansas • Chula Vista, California • Los Angeles, California + 54 more
Conditions
Decompensated Cirrhosis
Interventions
Emricasan (25 mg), Emricasan (5 mg), Placebo
Drug
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
76
States / cities
Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 59 more
Conditions
Healthy Volunteers
Interventions
Sumatriptan, PF-06651600
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Stress Disorders, Post-Traumatic
Interventions
Risperidone, Placebo
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
20
States / cities
Tuscaloosa, Alabama • San Diego, California • San Francisco, California + 17 more